India’s Biocon Wins 1st Biosimilar Approval Of Herceptin; Will Launch Before March 2014
This article was originally published in PharmAsia News
Executive Summary
As the decks are cleared for an India launch of trastuzumab, Biocon and its global partner Mylan will be watched closely by both local and global competitors. The market impact in India will be most significant in terms of price, and it will test if Roche has played its cards right by aligning with local company Emcure.
You may also be interested in...
Kadcyla Positioned For Wide Use In Metastatic Breast Cancer
Roche is set to launch T-DM1 at the price of $9,800 a month, similar to cost of the preferred first-line regimen, which includes a combination of its own Perjeta and Herceptin. Drug was tested mostly in second-line HER-2 positive mBC, but labeling allows first-line treatment in a subset of patients at high risk.
Biologics Beckon: Biocon, Mylan Strike Deal; Combine To Take Teva, Sandoz Head-on
MUMBAI - Prospects for strong growth in the global generic biologics space in the next 10 years has brought together the world's third-largest generic drug maker Mylan and India's biotechnology company Biocon. The two signed a comprehensive deal that will share development and certain other costs to bring biologic drugs to the market
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.